CytomX Therapeutics, Inc. (CTMX)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1501989 · fiscal year ends in Dec
Closing price $2.27 on 29 Oct 2026; 52-week range $2.22 to $6.75.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $18.3M
- Revenue growth
- -87.0%
- Net income, last twelve months
- -$79.7M
- Operating margin
- -476.2%
- Net margin
- -435.2%
- Return on equity
- -26.4%
- Market value
- $495.7M
- Cash
- $17.2M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 217.9M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $76.2M | -$22.4M | -$17.4M | – | -$75.8M | 10-K filed 16 Mar 2026 |
| FY2024 | 31 Dec 2024 | $138.1M | $25.0M | $31.9M | $0.38 | -$86.5M | 10-K filed 6 Mar 2025 |
| FY2023 | 31 Dec 2023 | $101.2M | -$6.5M | -$569.0K | -$0.01 | -$56.9M | 10-K filed 11 Mar 2024 |
| FY2022 | 31 Dec 2022 | $53.2M | -$101.3M | -$99.3M | -$1.51 | -$112.5M | 10-K filed 27 Mar 2023 |
| FY2021 | 31 Dec 2021 | $37.3M | -$116.0M | -$115.9M | -$1.81 | -$120.6M | 10-K filed 1 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $1.4M | -$20.7M | -$0.09 |
| Q1 FY2026 | 31 Mar 2026 | $10.3M | -$18.2M | -$0.10 |
| Q4 FY2025 | 31 Dec 2025 | $663.0K | -$26.5M | – |
| Q3 FY2025 | 30 Sep 2025 | $6.0M | -$14.2M | -$0.09 |
| Q2 FY2025 | 30 Jun 2025 | $18.7M | -$154.0K | $0.00 |
| Q1 FY2025 | 31 Mar 2025 | $50.9M | $23.5M | $0.27 |
| Q4 FY2024 | 31 Dec 2024 | $38.1M | $18.9M | $0.22 |
| Q3 FY2024 | 30 Sep 2024 | $33.4M | $5.7M | $0.07 |
Company events
The newest 8-K filings of 132 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 27 Jul 2026 | 8-K | Leadership change | 5.02 |
| 22 Jun 2026 | 8-K | Leadership change, Shareholder vote, Bylaws or fiscal year change | 5.02, 5.03, 5.07, 9.01 |
| 3 Jun 2026 | 8-K | Material agreement | 1.01 |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 |
| 19 Mar 2026 | 8-K | Other events | 8.01, 9.01 |
| 16 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 6 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 13 Aug 2025 | 8-K | Other events | 8.01 |
| 7 Aug 2025 | 8-K | Results | 2.02, 9.01 |
| 13 Jun 2025 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
| 28 May 2025 | 8-K | Other events | 8.01 |
Every filing
The newest filings with the SEC of 285 held.
| Filed | Form | Period |
|---|---|---|
| 6 Aug 2026 | S-8 | – |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 27 Jul 2026 | 8-K | 24 Jul 2026 |
| 22 Jun 2026 | 8-K | 17 Jun 2026 |
| 3 Jun 2026 | 8-K | 29 May 2026 |
| 7 May 2026 | 8-K | 7 May 2026 |
| 7 May 2026 | 10-Q | 31 Mar 2026 |
| 30 Apr 2026 | DEFA14A | – |
| 30 Apr 2026 | DEF 14A | 17 Jun 2026 |
| 20 Apr 2026 | PRE 14A | 17 Jun 2026 |
| 19 Mar 2026 | 8-K | 17 Mar 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 15 Jun 2026 | Ogden Christopher, Chief Financial Officer | Sale outside a trading plan | 1,624 | $3.05 | $5.0K | 295,324 | 17 Jun 2026 |
| 17 Mar 2026 | Chu Yu-Waye, Chief Medical Officer | Sale outside a trading plan | 21,279 | $6.42 | $136.7K | 189,446 | 19 Mar 2026 |
| 17 Mar 2026 | Mccarthy Sean A., CEO | Sale under a trading plan | 118,969 | $6.42 | $764.1K | 1,078,922 | 19 Mar 2026 |
| 17 Mar 2026 | Belvin Marcia, SVP, Chief Scientific Officer | Sale outside a trading plan | 31,492 | $6.42 | $202.3K | 300,760 | 19 Mar 2026 |
| 17 Mar 2026 | Ogden Christopher, Chief Financial Officer | Sale outside a trading plan | 19,323 | $6.42 | $124.1K | 296,948 | 19 Mar 2026 |
| 6 Nov 2025 | Mccarthy Sean A., CEO | Sale under a trading plan | 101,793 | $4.54 | $461.9K | 987,891 | 10 Nov 2025 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 6 Nov 2025 | Sean McCarthy, CEO | 101,793 | $461.9K | 6 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 28 Oct 2026 | BANK OF AMERICA CORP /DE/ | 13G amended | 5.4% | 11.9M |
| 14 Aug 2026 | Kynam Capital Management, LP | 13G amended | 9.96% | 0 |
| 14 Aug 2026 | Point72 Asset Management, L.P. | 13G amended | 3.6% | 7.8M |
| 7 Aug 2026 | STATE STREET CORPORATION | 13G | 5.4% | 11.7M |
| 3 Aug 2026 | BANK OF AMERICA CORP /DE/ | 13G | 7% | 15.1M |
| 27 Jul 2026 | BlackRock, Inc. | 13G | 7.6% | 16.6M |
| 15 May 2026 | Kynam Capital Management, LP | 13G amended | 6.9% | 0 |
| 15 May 2026 | Venrock Healthcare Capital Partners III, L.P. | 13G amended | 4.6% | 10.0M |
| 15 May 2026 | Longitude Capital Partners V, LLC | 13G amended | 7% | 15.3M |
| 15 May 2026 | Perceptive Advisors LLC | 13G amended | 4.6% | 10.1M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 42.8M | +4.84% | 13.78 |
| 30 Sep 2026 | 40.8M | +5.63% | 8.67 |
| 15 Sep 2026 | 38.6M | +15.3% | 9.29 |
| 31 Aug 2026 | 33.5M | -3.2% | 11.81 |
| 14 Aug 2026 | 34.6M | -1.4% | 15.93 |
| 31 Jul 2026 | 35.1M | -12.92% | 11.78 |
| 15 Jul 2026 | 40.3M | +13.37% | 10.38 |
| 30 Jun 2026 | 35.6M | +16.21% | 4.32 |
Funds that hold it
From each fund's latest Form 13F.
223 funds held it at 30 Jun 2026: 115 added and 33 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| FMR LLC | 32,714,937 | $122.7M | +759,300 |
| Kynam Capital Management, LP | 21,703,093 | $81.4M | +6,690,000 |
| BlackRock, Inc. | 17,559,822 | $65.8M | +12,331,542 |
| Bank of America Corp. | 15,082,617 | $56.6M | +4,879,832 |
| State Street Corp. | 11,747,236 | $44.1M | +6,083,828 |
| Perceptive Advisors LLC | 10,439,185 | $39.1M | +340,361 |
| Vanguard Capital Management LLC | 8,525,457 | $32.0M | -207,661 |
| Point72 Asset Management, L.P. | 7,811,033 | $29.3M | -64,357 |
| Wellington Management Group LLP | 5,168,961 | $19.4M | +1,585,976 |
| Venrock Adviser, LLC | 4,982,124 | $18.7M | -5,000,000 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B